A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

NCT04740034 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor strategic decision

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: AMG 340

Sponsor

Amgen